Navigation Links
Cordex Pharma Forms Heart Failure Medical Advisory Board
Date:2/11/2009

s perhaps one of the largest untapped pharmaceutical markets. Currently available drugs prolong the lives of patients with this condition, however, surprisingly little innovative research is being translated to new medicines. With the help of our Medical Advisory Board, we hope to demonstrate the clinical safety and efficacy of CDP-1050 in an efficient and convincing manner to the satisfaction of the medical community and regulatory authorities alike. Eventually, we hope to make the drug available to treat the desperately ill heart failure patients worldwide."

About Heart Failure

Heart failure, a condition characterized by the inability of the heart to effectively pump blood as well as by fluid accumulation in the lungs and other tissues, is suffered by an estimated five million Americans and is responsible for 300,000 deaths in the U.S. annually, according to the National Heart, Lung and Blood Institute. It is the single largest Medicare expense, at a cost of $33.2 billion each year. The five-year mortality rate with heart failure can be as high as 50 percent.

About CDP-1050

CDP-1050 is an investigational drug candidate for the treatment of heart failure. The drug is designed to correct the nitric oxide and redox imbalance in the failing heart and the cardiovascular system. CDP-1050 has a dual mechanism of action; it inhibits the production of excessive reactive oxygen radicals and restores nitric oxide to physiologic levels. The primary therapeutic target is the ryanodine receptor, the main ion channel in the heart that supplies the calcium necessary for the heart to contract. CDP-1050 is expected to enter a Phase 2 clinical trial this year.

About Cordex Pharma, Inc.

Cordex is a specialty pharmaceutical company that develops new cardiovascular medicines based upon the emerging pharmacology of adenosine triphosphate (ATP) and nitric oxide (NO). These two
'/>"/>

SOURCE Cordex Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cordex Pharma Presents New Frontiers in Cardiovascular Medicines on January 29
2. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
3. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
6. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
7. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/5/2015)... GenomeDx Biosciences announced that it will present at ... Wednesday, August 12, in New York . ... about the company,s Decipher ®  test and an overview of ... The Decipher ®  Prostate Cancer Classifier is a highly ... and high risk prostate cancer. The test is the only ...
(Date:8/5/2015)... (PRWEB) , ... August 05, 2015 , ... ... to aid the transition from legacy tubes, with 2D barcode labels on the ... decodes 100 legacy tube 2D barcodes in 1 second, using FluidX’s IntelliCode software, ...
(Date:8/4/2015)... (NYSE: BIOA ), a leader in renewable materials ... June 30, 2015. Highlights included: , The Sarnia plant ... final cost of the Sarnia plant is projected to ... end of the estimate communicated at the onset of ... company announced commercial collaborations in two targeted industry segments; ...
(Date:8/4/2015)... -- Trigemina, Inc., a biopharmaceutical company focused on the ... products, announced today that the company has appointed Shashidhar ... officer. Dr. Kori brings over 30 years of clinical ... focused in the neuroscience and headache space. ... clinical team given his vast experience managing clinical development ...
Breaking Biology Technology:GenomeDx Biosciences to Present at 2015 Wedbush PacGrow Healthcare Conference 2GenomeDx Biosciences to Present at 2015 Wedbush PacGrow Healthcare Conference 3RURO Announces FreezerPro® 7 Integration with Top-down 2D barcode scanners by FluidX 2BioAmber Reports Second Quarter 2015 Financial Results 2BioAmber Reports Second Quarter 2015 Financial Results 3BioAmber Reports Second Quarter 2015 Financial Results 4BioAmber Reports Second Quarter 2015 Financial Results 5BioAmber Reports Second Quarter 2015 Financial Results 6BioAmber Reports Second Quarter 2015 Financial Results 7BioAmber Reports Second Quarter 2015 Financial Results 8BioAmber Reports Second Quarter 2015 Financial Results 9BioAmber Reports Second Quarter 2015 Financial Results 10BioAmber Reports Second Quarter 2015 Financial Results 11BioAmber Reports Second Quarter 2015 Financial Results 12Trigemina Appoints Dr. Shashi Kori to the Position of Chief Medical Officer 2Trigemina Appoints Dr. Shashi Kori to the Position of Chief Medical Officer 3
... and RESEARCH TRIANGLE PARK, N.C., June 8 CSL Limited ... have mutually agreed to terminate their merger agreement, announced on ... for US$3.1 billion in cash. , , Dr. Brian ... are disappointed that the U.S. Federal Trade Commission (FTC) resolved ...
... , , INCLINE VILLAGE, Nev., June 8 ... announced revenue guidance for the second quarter ended June 30, ... for the second quarter of 2008. The increase is due ... Avastin(R), and Lucentis(R), which are marketed by Genentech, and sales ...
... a west coast session of NCCN Academy for Excellence ... Business scheduled for July 9 - 10, 2009 in ... give pharmaceutical and biotech professionals the rare opportunity to ... operational issues from the provider and payer perspective. , ...
Cached Biology Technology:CSL Limited and Talecris Biotherapeutics Agree to Terminate Merger Agreement 2CSL Limited and Talecris Biotherapeutics Agree to Terminate Merger Agreement 3PDL BioPharma Provides Second Quarter 2009 Revenue Guidance of Approximately $125 Million 2PDL BioPharma Provides Second Quarter 2009 Revenue Guidance of Approximately $125 Million 3Industry Professionals Get Schooled in Real-World Oncology Issues at NCCN Academy 2Industry Professionals Get Schooled in Real-World Oncology Issues at NCCN Academy 3Industry Professionals Get Schooled in Real-World Oncology Issues at NCCN Academy 4
(Date:7/9/2015)... DUBLIN , July 07, 2015 ... has announced the addition of the "Biometrics ... and Forecasts 2015-2020" report to their offering. ... a major contributor to this growth and the ... US$5.5 billion in revenue for companies involved in ...
(Date:7/9/2015)... JOSE, Calif. , July 9, 2015 ... the leading developer of human interface solutions, ... technology, the industry,s first fully hardware encapsulated ... Match-in-Sensor secure authentication technology is literally off ... storage and biometric matching within the fingerprint ...
(Date:7/8/2015)... FRANKLIN LAKES , N.J. and NEW YORK ... and Company) and Guidepoint today announced ... selected start-up healthcare companies with free access to Guidepoint,s ... mentoring several start-ups that are developing cutting-edge technologies to ... of a dedicated Guidepoint research manager, each start-up entrepreneur ...
Breaking Biology News(10 mins):Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3
... study shows that the exposure to the controversial chemical Bisphenol ... tests. In the study, researchers compared BPA concentrations in mice ... the day, compared to the more common lab method of ... BPA in the blood of mice. This is the ...
... knows that newborns still have a lot of neurological work ... variety of nascent animals, genes provide them with only a ... nervous system to do its own finish work. Two studies ... for exposure to light in the environment as mouse pups ...
... New York June 5, 2011 Moisture and ... form a critical nexus between surface hydrology and atmospheric ... has suggested that soil moisture has had a positive ... observations of this. A team of researchers from Columbia ...
Cached Biology News:Exposure to BPA has been underestimated, new MU research says 2Early light refines the brain's circuitry for vision 2Early light refines the brain's circuitry for vision 3Early light refines the brain's circuitry for vision 4Columbia Engineering team makes major step in improving forecasts of weather extremes 2
Fast, sensitive quantitation of total MEK 1/2 concentration....
Argon Calibration Source...
RayBio Human Chemokine Antibody Array 1.1 (8) with Accessory, detects 38 chemokine factors (for lysate) Class: Antibody Array Products Product Group: Antibody Array...
Vybrant® Multidrug Resistance Assay Kit...
Biology Products: